ClinicalTrials.gg
RecruitingNCT06434493EMPHATICUpdated Nov 10, 2026

Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma

An interventional study of Proton Beam Therapy and Concurrent oral capecitabine chemotherapy in Cholangiocarcinoma, sponsored by The Christie NHS Foundation Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by The Christie NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 10, 2026Now RecruitingFirst site in United Kingdom+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Cholangiocarcinoma with a site in United Kingdom — 11 open to participants now, 16 under way, 6 of them phase 3. Cholangiocarcinoma · United Kingdom.

Planned enrollment
32nd of 38
30 · median 170
Started
2025
with 3 others
No phase
2 of 46
2 open now
Primary completion
2029-11
later than 13 of 15 live
Registered
39th of 46
by date
Lead sponsor
3 of 46
The Christie NHS Foundation Trust

Among the 46 studies in Cholangiocarcinoma with a site in United Kingdom, this one is the 32nd largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 with no phase, reaches primary completion later than 13 of the 15 other live ones, and was the 39th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

11 of the 46 studies in Cholangiocarcinoma with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 17 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Cholangiocarcinoma with a site in United Kingdom, or all of them as a file.
02

Study summary

Proton Beam Therapy (PBT) is an advanced radiotherapy technique. There are two National Health Service (NHS) PBT treatment centres in the United Kingdom (UK), in Manchester and London. The NHS is committed to ensuring the best use of this limited resource by investigating which patients will benefit from PBT.

Evaluative Commissioning in Protons (ECIP) is a programme of studies exploring the role of PBT in different types of cancer. The studies are funded by NHS England. ECIP studies are not randomised studies, which means that all eligible patients will be offered PBT. Any eligible patient in the UK can be referred, and accommodation is available for patients who don't live close to a PBT centre.

The main benefit of PBT, compared with standard photon radiotherapy, is the predicted reduction in radiation dose to surrounding healthy tissues. With photon radiotherapy, some radiation passes beyond the target area, affecting healthy tissues and causing side-effects. With PBT, the radiation dose stops within the target area, causing less damage to surrounding tissues, and limiting side effects.

EMPHATIC is a study within the ECIP programme. In EMPHATIC, the investigators are looking to see whether a combination of treatments, including PBT, chemotherapy and a liver transplant, can be used to treat patients with cholangiocarcinoma (bile duct cancer).

EMPHATIC offers patients whose cancer can't be removed with surgery (unresectable) a potentially curative treatment option. There is evidence that liver transplant is a curative treatment option in patients with cholangiocarcinoma. There is a risk that the cancer may grow or spread whilst waiting for a transplant, potentially making patients ineligible. PBT and chemotherapy is thought to be the best way to control the cancer, until a liver transplant can be performed. EMPHATIC will look at how a combination of PBT and chemotherapy, followed by a liver transplant, can be used to curatively treat patients with unresectable cholangiocarcinomas.

Read the detailed description

Liver and bile duct resection with lymphadenectomy is the standard of care for patients with hilar cholangiocarcinoma. Unfortunately, resection is only possible in a minority of patients for many reasons including, the extent of cancer or the presence of background primary sclerosing cholangitis (PSC). For patients with a background of PSC, liver transplantation is a potential treatment, and it was recently approved as an indication for a commissioned pilot service evaluation of liver transplantation in the UK.

Until recently, the use of liver transplantation for hilar cholangiocarcinoma was confined to a few centres in the United States. The initial publications from the Mayo Clinic and Nebraska, as well as more recent experience from other centres, support strict selection protocols to identify patients likely to benefit from liver transplantation. In 2000, the initial experience at the Mayo Clinic in which 19 patients enrolled in a pre-transplant neoadjuvant therapy protocol was published. 11 patients underwent subsequent liver transplantation. Of the 8 with long term follow up (median 44 months), only one patient developed cancer recurrence. Similarly, the long-term experience of patients in Nebraska, where 11 patients underwent liver transplantation after neoadjuvant chemoradiotherapy was published in 2002. 5 of the 11 patients were alive and disease free at a median follow up of 7.5 years .

Most recent experience is based on adopting the Mayo protocol. In general, the inclusion criteria define patients with early cancers, with a dominant stricture or tumour less than 3cm. Intra and extrahepatic disease including any site of nodal metastases precluded selection. Controversially, histology or cytology was not considered essential for diagnosis of cholangiocarcinoma by most centres. Elevated Ca 19.9 of >100, Fluorescence In Situ Hybridization (FISH) polysomy 9p21 or tumour mass in the presence of a dominant stricture were considered sufficient for enrolment. Prior (attempts at) trans-peritoneal biopsy was another exclusion criterion based on concerns of increased risk of tumour dissemination. Neoadjuvant therapy involved external beam radiation therapy (EBRT) with concurrent chemotherapy (chemo sensitisation), followed by brachytherapy whenever possible. Patients were then re-staged and remain on systemic chemotherapy until the time of transplant.

A recent review looked at all studies from 2000 until 2019. 20 studies with 428 patients were eligible for analysis. The pooled 1, 3-, and 5-year overall survival rates following liver transplantation without neoadjuvant therapy (n=156) were 71.2%. In patients who had neoadjuvant therapy prior to transplantation (n=272), the survival improved to 82.8% at 1,3 and 5 years respectively.

The cancer recurrence rate was 51.7% in patients who did not receive neoadjuvant therapy compared to 24.1% for patients who had. Only 4 of the 20 studies reported pre-transplant histological confirmation of adenocarcinoma or malignant/suspicious cells on cytology. 98% of liver explants from studies not using neoadjuvant therapy confirmed malignancy, compared to 50.5% in those who had received neoadjuvant therapy. Patients in whom malignancy was not found are presumed to have had complete pathological response to neoadjuvant therapy (approximately 50% following neoadjuvant therapy). Patients with background PSC had better outcomes compared to patients with de novo cancers.

Study Design \& development of an evaluative commissioning study within ECIP:

It is not possible to design EMPHATIC, a study for patients with unresectable cholangiocarcinoma, as a randomised controlled trial (RCT), because there is no ethically acceptable control arm. In an RCT, patients in a theoretical control arm would be offered either no transplant, or no neoadjuvant therapy prior to the transplant. Based on the published literature summarised above, the adverse anticipated outcomes of patients in such a control arm would not be considered justified.

Neoadjuvant therapy is required to control the tumour prior to transplant. In the Mayo protocol described above, patients received external beam (chemo)radiotherapy followed by brachytherapy, and thereafter received chemotherapy until the time of transplant. Unfortunately, in the UK, brachytherapy services were not seen as a viable option, and hence the Mayo protocol is not feasible.

There is good scientific rationale that proton beam radiotherapy (PBT) offers the optimal technique for delivering neoadjuvant therapy as it is non-invasive, and spares as much functional liver as possible, compared with alternatives such as photon-EBRT techniques or invasive techniques (e.g. brachytherapy). Compared with photon-EBRT techniques, PBT delivers highly conformal radiotherapy, with a significantly reduced integral body dose, and no exit beam. It is expected to be associated with an improved toxicity profile.

03

Conditions studied

  • Cholangiocarcinoma

Browse trials for

Keywords

  • proton beam therapy
  • protons
  • evaluative commissioning
  • liver transplant
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General criteria

  • Age 17 years and over
  • Performance status 0 or 1 ()
  • Suitable for liver transplantation as determined by Multi Disciplinary Team (MDT)
  • Able to tolerate therapy.
  • A history of primary sclerosing cholangitis (PSC) will be a necessary eligibility criterion at the start of the study. Part-way through recruitment to the study, the eligibility criteria may be broadened, allowing patients with sporadic / non-PSC unresectable cholangiocarcinoma to also be considered. The decision to do this will be taken by the Study Management Group, who will be monitor results closely, following an interim analysis after the first 10 patients. Suitability for Orthotropic Liver Transplant will continue to be confirmed in the regional Hepato Biliary cancer MDT.

Specific criteria

  • Presence of a dominant hilar stricture or mass \<3cm on cross-sectional imaging
  • proven cholangiocarcinoma by brush cytology or via Endoscopic Retrograde Cholangiopancreatography (ERCP) or Percutaneous Transhepatic Cholangiography (PTC)
  • No disease, including to regional lymph nodes.

Exclusion criteria

Exclusion Criteria:

General criteria

  • Inability to consent
  • Poor performance status
  • Failed fitness assessment
  • Extrahepatic disease at any stage of presentation, assessment and treatment
  • Prior biliary resection or hilar dissection for attempted resection within the past 12 months
  • Prior in the last 5 years (excluding early breast, prostate, cervix and non melanoma skin cancers)

Specific criteria

  • Estimated (eGFR) \<30
  • Prior radiation to the upper abdomen
  • Uncontrolled infection
  • Duodenal invasion
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Proton Beam Therapy

    All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy), and alongside concurrent oral capecitabine 625mg/m2 twice daily on radiation days.

    Radiation: Proton Beam Therapy · Drug: Concurrent oral capecitabine chemotherapy · Drug: Cisplatin & Gemcitabine intravenous chemotherapy · Procedure: Orthotropic Liver Transplant

Interventions

  • RadiationProton Beam Therapy

    All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)

  • DrugConcurrent oral capecitabine chemotherapy

    All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days

  • DrugCisplatin & Gemcitabine intravenous chemotherapy

    Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.

  • ProcedureOrthotropic Liver Transplant

    If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.

06

What researchers measure

Primary outcomes

  1. Incidence of Common Toxicity Criteria for recording Adverse Events (CTCAE) Grade 3 and above toxicity

    Incidence of Grade ≥ 3 toxicity using CTCAE (grades 0-5) up to 90 days following completion of neoadjuvant (chemo)-PBT and liver transplant. Higher score indicates worse outcome.

    Time frame: Up to 90 days post neoadjuvant chemo-radiation.

  2. Proportion of patients who undergo a successful liver transplant

    The proportion of patients who, following neoadjuvant (chemo)-PBT, undergo a successful liver transplant (measured at 90 days post-transplant).

    Time frame: 90 days post transplant.

Secondary outcomes

  1. Number of patients completing planned radiotherapy

    Number of patients completing planned radiotherapy

    Time frame: Up to 1 year

  2. Incidence of severe treatment related side effects

    Rate of Common Toxicity Criteria for recording Adverse Events (CTCAE) Grade 3 and above toxicity (Grades 0-5). Higher score may mean a worse outcome.

    Time frame: Up to 2 years

  3. 1 year post completion of neoadjuvant therapy cancer-related mortality

    Calculated from date of last PBT treatment and defined as time to death or censoring at 1 year.

    Time frame: At 1 year

  4. 1 year post transplant overall survival

    Calculated from date of liver transplant and defined as time to death or censoring at 1 year.

    Time frame: At 1 year

  5. 1 year post transplant graft survival

    Calculated from date of transplant and defined as time to death or censoring at 1 year.

    Time frame: At 1 year

  6. 1 year post listing patient survival

    Calculated from the date the patient was added to the transplant waiting list and defined as time to death or censoring at 1 year.

    Time frame: At 1 year

  7. Disease free survival from transplant

    Calculated as time to cancer recurrence or death whichever is earliest, from date of transplant, with censoring at 1 year.

    Time frame: At 1 year

  8. Recurrent cancer within 6 months of transplant

    Described as local, regional or metastatic disease

    Time frame: Up to 6 months following transplant

  9. Cancer control at time of transplant

    Reported as time to loss of cancer control with censoring at time of transplant

    Time frame: Up to 2 years

  10. Cancer control at time of removal from transplant list

    Reported as time to loss of cancer control with censoring at date of removal from transplant waiting list

    Time frame: Up to 2 years

  11. Transplant complication rates

    Surgical complication rates according to Clavien Dindo scale, measured from grades 1-5, higher grade may mean worse outcome.

    Time frame: Within 3 months of surgery

  12. Patient pathway

    Review of patient pathway deliverability defined as time interval from patient referral to the start of chemo-PBT treatment

    Time frame: Up to 2 years

  13. Time to completion of neoadjuvant chemo-PBT treatment to liver transplant

    Measured in days from last day of PBT to date of transplant

    Time frame: Up to 2 years

  14. Time spent on transplant waiting list

    Measured in weeks from transplant listing date to liver transplant date

    Time frame: Up to 2 years

  15. Referral rates

    Review annual referral rates to the study

    Time frame: At 6 months, 12 months, 18 months and 24 months following the opening of the study

  16. Recruitment rates

    Number of patients participating in the study

    Time frame: At 6 months, 12 months, 18 months and 24 months following the opening of the study

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000 May;6(3):309-16. doi: 10.1053/lv.2000.6143. PubMed 10827231 ↗
  • Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep;2(8):774-9. doi: 10.1034/j.1600-6143.2002.20812.x. PubMed 12243499 ↗
  • Cambridge WA, Fairfield C, Powell JJ, Harrison EM, Soreide K, Wigmore SJ, Guest RV. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. Ann Surg. 2021 Feb 1;273(2):240-250. doi: 10.1097/SLA.0000000000003801. PubMed 32097164 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2029, 48 months after the start.

Of 66 non-industry interventional studies with no phase under Cholangiocarcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28. This study's planned 48 months is above that.

Counting every sponsor, half of 67 studies reached it within 43 months; a quarter within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Nov 2024 → Oct 2025, primary completion Jun 2028 → Nov 2029 and completion Jun 2029 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
May 30, 2024
StartActual
Oct 3, 2025was Nov 2024
Primary completionEst.
Nov 1, 2029was Jun 2028
CompletionEst.
Nov 1, 2029was Jun 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
2 sites added — first site in United Kingdom
Show 2 added (2 United Kingdom)
  • University College London Hospitals NHS Foundation Trust · London, United Kingdom
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
Nov 10, 2026
Start date
Nov 1, 2024→Oct 3, 2025 (actual)
Nov 10, 2026
Primary completion
Jun 1, 2028→Nov 1, 2029
Nov 10, 2026
Study completion
Jun 1, 2029→Nov 1, 2029
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United Kingdom
    Show 2 added (2 United Kingdom)
    • University College London Hospitals NHS Foundation Trust · London, United Kingdom
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    Start date Nov 1, 2024→Oct 3, 2025 (now actual)
    Primary completion Jun 1, 2028→Nov 1, 2029
    Study completion Jun 1, 2029→Nov 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06434493
Collaborators
University College London Hospitals, University College, London, Royal Free Hospital NHS Foundation Trust
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Oct 3, 2025
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Romelie Rieu
Contact
romelie.rieu@nhs.net
0044 1619187172
Sally Falk
Contact
sally.falk@nhs.net
0044 1619187172
Maria Hawkins
principal investigator · University College, London
Douglas Thorburn
principal investigator · The Royal Free NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion